用于治疗儿童恶性肿瘤的分子靶向疗法的开发。
Development of Molecularly Targeted Therapies to Treat Pediatric Malignancies.
作者信息
Stewart Clinton F, Robinson Giles W
机构信息
Department of Pharmaceutical Sciences, St. Jude Children's Research Hospital, Memphis, Tennessee, USA.
Department of Oncology, St. Jude Children's Research Hospital, Memphis, Tennessee, USA.
出版信息
Clin Pharmacol Ther. 2017 Nov;102(5):752-753. doi: 10.1002/cpt.785. Epub 2017 Aug 24.
Drugs and biologics developed to treat children with cancer have been historically developed in adults for adult indications. Although leading to many useful drugs and biologics to treat pediatric cancer, future development of molecularly targeted therapies (MTTs) should be directed toward pediatric tumors more specifically to maximize antitumor efficacy while minimizing acute morbidity and long-term disability. This will put pediatric clinicians closer to the goal of cure for all children diagnosed with cancer.
历史上，用于治疗儿童癌症的药物和生物制品都是先在成人中研发用于成人适应症。尽管这带来了许多治疗儿童癌症的有用药物和生物制品，但分子靶向疗法（MTTs）的未来发展应更具体地面向儿童肿瘤，以在将急性发病率和长期残疾降至最低的同时最大化抗肿瘤疗效。这将使儿科临床医生更接近治愈所有被诊断患有癌症儿童的目标。
Zotero 插件